actually dndn is the wrong stock to be comparing appy to. The right one is hgsi. Its almost creepy how similar these stocks look just before a move up. Pull up hgsi chart just before its move up and appy chart and look at them. FREAKY!!!!! And we all remember hgsi going up from $3.75 to $15 the day their trial results were released and appy has a much much smaller float.
That 83% was skewed by that one suburban hospital. Without it the npv would have been .97%. Now, one huge thing appy has goin for herself over dndn is cost. The biggest reason to integrate appyscore is cost savings. Third world countrys that only use their ct scanners for people that are basically already dead will love it. I agree we have ta see the test results. And if they are good I dont see why it shouldnt trade for $10 immediately after. Christ I know pinksheet scam stocks with higher market caps than appy has rie now.
While I do tend to agree, they're two very different companies. However, both have unique products to general public. While DNDN is heavily favorite in USA, AppyScore can be easily used world wide. I believe Market Cap of 1.5B or more.
I'm all about it but our lives hang in AspenBio's hands. We have to see how good the new test is, and what are the new NPV numbers. If they exceed above 96%, we should be golden. I'm still wondering how they loosened the sensitivity to achieve higher NPV's. I wish someone knew more technical values of the improvement of the prior 83%.
I disagree. Their trial ended mid quarter so they probably brought their operating income down considerably. Earnings are expected to be $100k which is a net loss of .09 per share. I believe those estimates will be beaten by $200k dollars which equates to a loss of .06 per share. I expect a pr reading- "APPY reduces operating expenses by 30%". with the most recent dilution the company now has a cash position of over $20M with $6M in liabilities. Put a pe of 15 on that and you start to see how we are already grossly undervalued.